Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2007

View Archived Issues

Enzymatic combinatorial approach for synthesizing new anticoagulant heparan sulfate derivatives

Alte Biosciences secures rights for therapeutics targeting late-onset depression

Positive phase IIb results for elocalcitol in BPH

Phase II omiganan study demonstrates positive results

Allergan acquires Esprit Pharma

EnVivo reports progress on major drug programs

Novel contraceptive agents reported in recent Wyeth patent

Phase I testing commences for SAR-3419 in non-Hodgkin's lymphoma

Positive interim safety data found for Vical's phase II CMV vaccine trial

Second OvaRex MAb phase III trial reaches 118th relapse event

Pharmion initiates pivotal phase III amrubicin study in small cell lung cancer

Genentech announces third quarter 2007 results

ConjuChem reports final results of PC-DAC:Exendin-4 phase I/II trial

Initial results of phase II boceprevir study show high early virologic response

Affectis initiates phase II trial for cimicoxib in depression

Galenica acquires Aspreva

Isis adds new drug, ISIS-388626, to pipeline for the treatment of type 2 diabetes

Recent Prolysis patent discloses new antiinfective agents

Novel agents for treating diabetes disclosed in recent patent literature

Micromet receives regulatory approval to conduct a phase II MT-103 trial

Analysis of phase III desmoteplase trial justifies continued development

Abraxis BioScience's Abraxane receives positive opinion in Europe

Neuroprotection by C2-8, a polyglutamine aggregation inhibitor, in Huntington's disease model

GlaxoSmithKline's once-daily Avamys receives positive opinion in Europe

FDA approves sanofi pasteur's meningococcal vaccine for children

Targin improves opioid-induced bowel dysfunction in patients with chronic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...